Bernard Klein

Title: Bernard Klein: Innovator in Multiple Myeloma Treatment

Introduction

Bernard Klein is a notable inventor based in Montpellier, France. He has made significant contributions to the field of medical research, particularly in the treatment of multiple myeloma. With a total of 2 patents, his work focuses on methods that enhance the understanding of patient responses to specific cancer treatments.

Latest Patents

Klein's latest patents include innovative methods for predicting response to combination treatments involving histone deacetylase inhibitors (HDACi) and DNA methyltransferase inhibitors (DNMTi) in patients suffering from multiple myeloma. The first patent outlines a comprehensive method that involves determining the expression levels of selected genes in biological samples, comparing these levels to predetermined reference values, and calculating a score to predict treatment response. The second patent similarly focuses on predicting responses to HDACi treatments, utilizing a method that assesses gene expression levels and compares them to reference values to determine patient outcomes.

Career Highlights

Throughout his career, Bernard Klein has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and the Université de Montpellier. His research has been pivotal in advancing the understanding of cancer treatment responses, particularly in the context of multiple myeloma.

Collaborations

Klein has collaborated with various professionals in his field, including his coworker Jérôme Moreaux. These collaborations have contributed to the development of his innovative patents and research methodologies.

Conclusion

Bernard Klein's contributions to the field of medical research, particularly in the treatment of multiple myeloma, highlight his role as an influential inventor. His innovative methods for predicting treatment responses are paving the way for more personalized and effective cancer therapies.